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Abstract— Malaria is a major public health problem 
associated with high mortality, morbidity rates and undue 
economic burden in sub-Saharan countries. Presently, 
every year, 300 to 500 million people suffer clinically from 
malaria and 90% of them in sub-Saharan Africa. About 
1.5 to 3 million people die of malaria every year and 85% 
of these occur in Africa. One child dies of malaria 
somewhere in Africa every 20 second, and there is one 
malarial death every 12 sec somewhere in the world. This 
is also a damaging economic burden for these sub-Saharan 
Africa countries as huge work force time and resources are 
expended for treatment. Plasmodium falciparum (hence 
forth Pf) is the most severe of all the human malaria 
parasites. This organism is continuing to develop 
resistance to all known drugs and therapeutic regime.  One 
of the mechanisms of resistance in Pf is the modification of 
the drug target. Hence, it is expedient to continuously 
discover novel drug targets in Pf and to discover or 
develop new drugs against such targets. Drug-able 
signaling pathways have been shown to have inherent 
mechanism capable of deterring drug resistance. Using 
computational techniques, we have identified some 
proteins in the signaling pathways of Pf as putative targets 
for anti-plasmodia drug. RNA pseudouridylate synthase, 
which also plays a key role in RNA synthesis and 
ribosomal function, is one of such proteins. Initial virtual 
screening of this enzyme against drug and chemical 
databases has been performed to identify compounds that 
can inhibit this enzyme. This led us to compounds which 
inhibit nucleotide metabolism. This is a work in progress 
whose current state is hoped for presentation at this 
conference. In order to determine the identified 
compounds IC50, the identified compounds will be 
screened in vitro against the enzyme. We have currently 
completed the establishment of the enzyme functionally 
expression in E. coli and purification. Thereafter, the 
drugs will be screened for their anti-plasmodia activity 
using cultured Pf and the IC50 for each drug will be 
determined. In order to assess their safety, the selectivity 
index of compounds that showed in vitro anti-plasmodia 
activity will be determined using human cultured cell lines. 
The last stage of this study will involve screening the 
compounds in an in vivo mouse model of malaria. It is 
hoped that the result of this study will prove this enzyme 
as a novel target for antimalarial drug. And provide as 
input, critical drug targets in to our established Structure 
Based Drug Design (SBDD) pipeline. 
Keywords: Drug design, Plasmodium falciparum, RNA 
pseudouridylate synthase, drug target, Virtual Screening, 
anti-plasmodial 
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I. INTRODUCTION 
Malaria has been reported to be one of the major causes of 
death worldwide, with more than 90% in Africa alone. In 
2013, an estimated 128 million people were infected with 
Plasmodium falciparum in sub-Saharan Africa at any one 
time. In total, 18 countries account for 90% of infections in 
sub-Saharan Africa; 37 million infections (29%) arose in 
Nigeria and 14 million (11%) in the Democratic Republic of 
the Congo, the two countries with the highest numbers of 
infections [1]. These may clearly pose a major obstacle to 
sustainable development [2]. In Sub-Saharan Africa, malaria is 
directly responsible for one in five childhood deaths and acts 
in synergisms with other illness such as respiratory infections 
which cause even higher proportion of childhood morbidity 
and mortality [3].  
Plasmodium parasites have been implicated to be the 
underlying genesis of the disease, among which five species 
that infect humans have been reported [4]. One of them which 
is Plasmodium falciparum, the main species associated with 
complicated malaria cases such as black water fever [5]. Quite 
unfortunate, this organism is continuing to develop resistance 
through a biochemical modification of the drug target to all 
known drugs and therapeutic regime. This necessitate 
continuously search for the novel drug targets in an attempt to 
develop new drugs against them. The toxicological 
implication of the currently available and commercialized 
antimalarial drugs is another issue of major concern [6].  
The conversion of uridylate to pseudouridylate occurs in 
all three domains of life and is the most common 
posttranscriptional modification of RNA [7]. This is being 
carried out by RNA pseudouridylate synthase, an enzyme that 
basically modifies some specific uridylate residues along the 
T- arm stem loop, anticodon stem loop of transfer RNA vis-à-
vis during the splicing of pre-messenger RNA at the critical 
levels of posttranscriptional modification, relative to gene 
ontology. Certain critical aspartic acid residues have been 
reported to be the main actors when it comes to catalytic 
activity RNA pseudouridylate synthase [7]–[9].  
Drug-able signaling pathways have been shown to have 
inherent mechanism capable of deterring drug resistance. 
Using computational techniques (see details under the 
“Materials and methods” below), some proteins have been 
identified in the signaling pathways of Plasmodium falciparum 
as putative targets for anti-plasmodia drug. RNA 
pseudouridylate synthase, which also plays a key role in RNA 
synthesis and ribosomal function, is one of such proteins.  
Initial virtual screening of this enzyme against drug and 
chemical databases has been performed to identify compounds 
that can inhibit this enzyme. This led us to compounds which 
inhibit nucleotide metabolism. This is a work in progress 
whose current state is hoped for presentation at this 
conference. In order to determine the identified compounds 
IC50, the identified compounds will be screened in vitro 
against the enzyme. We have currently completed the 
establishment of the enzyme functionally expression in E. coli 
and purification. This is being reported in this write up. In a 
future work: The drugs will be screened for their anti-
plasmodia activity using cultured Pf and the IC50 for each 
drug will be determined. In order to assess their safety, the 
selectivity index of compounds that showed in vitro anti-
plasmodia activity will be determined using human cultured 
cell lines. The last stage of this study will involve screening 
the compounds in an in vivo mouse model of malaria. It is 
hoped that the result of this study will prove this enzyme as a 
novel target for antimalarial drug. And provide as input, 
critical drug targets in to our established Structure Based Drug 
Design (SBDD) pipeline. 
II.    MATERIALS AND METHODS 
A. Computational Analysis 
We begin this section by illustrating the success in our 
earlier computational analysis and then introduce the 
computational analysis that suggested RNA pseudouridylate 
synthase, on some signaling pathways, as a viable and novel 
antimalarial drug target. 
In Fatumo et al. [10-12], a computational method (Choke 
Point Analysis (CPA)) and pathway deviation analysis 
investigating the topology of biochemical metabolic networks 
[13-14] was developed to mine new essential enzymes serving 
as potential drug targets in the most deadly malaria parasite, 
Plasmodium falciparum. With this method, we predicted a 
refined list of drug targets of which one was validated 
experimentally using 6-diazo-5-oxonorleucine (DON) in Prof. 
Michael Lanzer’s laboratory at the University of Heidelberg, 
Germany, proving effective clearance of P. falciparum 
infected human blood cultures [15]. Specifically, we 
performed a half maximal inhibitory concentration (IC50) 
study and found that DON showed excellent antimalarial 
activity in-vitro when applied against P. falciparum Dd2 (3-4 
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x e-7 M, Fig. 1a). We performed positive control experiments 
using quinne and chloroquine. Quinne and chloroquine 
showed a slightly better dose response of 9.2 x e-08 and 4.7 x 
e-08 M, respectively (Fig. 1b). This success recorded in the in-
vitro experiments above was confirmed by an in-vivo study 
observing P. berghei infected mouse models (at Covenant 
University (CU)’s biological laboratory) [15]. Also 
specifically, we performed a mouse model study. P. berghei 
infected mice were injected intraperitoneally with DON 
dissolved in normal saline and parasitemia was observed 24 
and 72 h after treatment. Fig. 2 below shows the results for 24 
h. 24 h after treatment, 50% reduction of P. berghei was 
observed when administrating 12.5 mg/kg DON, and even 
80% reduction 72 h after treatment. At low concentrations (<6 
mg/kg), we observed an increase of parasitemia after 24 h. 
DON treated mice survived whereas all non treated mice died 
due to infection. 
 
Fig 1. The IC50 results of a) DON and b) quinne and 
chloroquine as positive controls. 
 
However DON is rather toxic and mutagenic, and hence 
can only be applied with care. Hence, further drug targets and 
drugs need to be exploited. The results obtained have been 
successful on one of the enzymatic sites listed in [10], and it 
demonstrates that the computational method works, that is, the 
predicted sites on the malaria parasite proved to be effective as 
drug targets. Benefits from this kind of work include that we 
may be able to produce novel antimalarial drugs, whose 
biological mode of action can be determined accurately [11] 
and obtained antimalarial drug target site upon which a 
powerful structure based drug design (SBDD) pipeline can be 
build. 
In a previous study, Oyelade et al.[16], we have 
constructed a protein–protein interaction network from the 
protein–protein interaction data obtained from the work of 
LaCount et al. [17]. Their results comprise 2846 interactions 
between 1308 proteins of P. falciparum in its intra-
erythrocytic cycle. In addition to the protein–protein 
interaction data, the transcriptional data from Le Roch et al. 
[18] and Bozdech et al. [19] were integrated to weigh the 
interaction reliabilities, depicted by the edges of the 
interaction graph. These probabilities were calculated under 
the logistic distribution given three variables, namely (i) the 
number of times an interaction between two proteins was 
observed, (ii) the Pearson correlation of expression 
measurements for the corresponding genes, and (iii) the 
proteins’ small world clustering coefficient [20]. We analyzed 
the resulting network using a linear-time algorithm for finding 
paths in a network under newly formulated biologically 
motivated constraints. Among others, we predicted a signaling 
pathway that may have been responsible for signaling the start 
of the invasion process of the Red Blood Cell (RBC) by the 
merozoites. The pathway is in line with earlier evidence that 
the RBC invasion required the cleavage of a surface protein on 
the RBC by a parasite serine protease [21]. All of the extracted 
signaling pathways (whose weight and hypergeometric p-
values are both less than 0,05) by Oyelade et al. are presented 
in Tables 2-8 of the supplementary materials associated with 
the paper, with a snapshot of these results presented in Tables 
1a-1e within the body of the paper and highlighted as red in 
Tables 2-8. It is also important to note that all these pathways 
are extracted bearing in mind certain identified classes of 
signal transduction pathways, namely, phosphatidylinositol 
cycle, calcium signaling, calcium modulated protein kinase, 
cyclic nucleotide dependent, cell cycle kinases, novel FIKK 
kinases proteins and proteins not known to belong to any 
signal transduction pathways. The readers are directed to 
Oyelade et al. for more details. 
Dastidar et al.[22] in their work about the involvement of 
P. falciparum protein kinase CK2 in the chromatin assembly 
pathway identified and listed in their Table 1, potential 
interactors in the nucleosome assembly and regulation 
pathway. We found that three of these proteins take part in 
some predicted signaling pathways of Oyelade et al [16] in 
Tables 2-8. These are extracted and listed in Table 1a below. 
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TABLE IA. PREDICTED MINIMUM PATHWAYS (POTENTIAL SIGNAL TRANSDUCTION PATHWAYS) BY Oyelade et al.[16] INVOLVING 
POTENTIAL INTERACTORS: PFL0185c, PF10_0232, and PFF1185 FROM TABLE 1 OF Dastidar et al [22].  
 
 
Column one indicates the name of the signaling pathway, 
the second column shows minimum paths extracted, while 
optimizing the identified number of proteins in the pathway 
under consideration. The third column shows the weight p-
value and column four detailed the products (from plasmodb) 
of the proteins in the identified potential signaling pathways. 
To validate the drug-ability of the predicted signaling 
pathways (in Oyelade et al [16]), we next compared their 
corresponding genes to all transcripts of the human genome 
using BLAST [23]. We produced in Table 1b below, genes  
 
with no significant homologies (all E-values > 0.01). Please 
note that the BLAST program used the new gene IDs for P. 
falciparum, we therefore linked these back to their old gene 
IDs as we have employed above. 
It is interesting to note that a drug-able site: PF11_0506, 
was found on the signaling pathway (in the FIKK family) we 
predicted in Oyelade et al. that ends up on a chloroquine 
resistance marker protein. This site automatically provided us 
with avenue to interfere with this pathway and possibly 
Name Minimum path p-value Details of genes 
 
Genes IDS 
 
Products 
Cell Cycle PF10_0272--->PFL0185c 0.009 PF10_0272 
PFL0185c 
60S ribosomal protein L3, putative 
Nucleosome assembly protein 1, putative 
FIKK PFA0130c ---> PFE1590w --->  PF10_0232 
 
 
0.009 PFA0130c 
PFE1590w 
PF10_0232 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
 PFA0130c ---> PFE1590w --->  PF10_0232---
>PF11_0506 
 
 
 
0.036 PFA0130c 
PFE1590w 
PF10_0232 
PF11_0506 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
Antigen 332, DBL-like protein 
 PFA0130c--->PFE1590w--->PF10_0232--->PFL1705w 0.039 PFA0130c 
PFE1590w 
PF10_0232 
PFL1705w 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
RNA binding protein, putative 
 PFA0130c--->PFE1590w--->PF10_0232--> PF14_0644 0.039 PFA0130c 
PFE1590w 
PF10_0232 
 
PF14_0644 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
conserved Plasmodium protein, unknown function 
 PFA0130c-->PFE1590w-->PFF0920c-->PF10_0232 0.036 PFA0130c 
PFE1590w 
PFF0920c 
PF10_0232 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
conserved Plasmodium protein, unknown function 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
Unknown 
genes 
PFA0125c--->PF08_0034-->PF10_0232--> PF11_0504 0.029 PFA0125c 
PF08_0034 
PF10_0232 
PF11_0504 
erythrocyte binding antigen-181 
histone acetyltransferase GCN5, putative 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
Plasmodium exported protein (hyp11), unknown 
function 
 PFA0125c-->PF08_0034-->PFI1715w-->PF10_0232--
>PF11_0504 
0.046 PFA0125c 
PF08_0034 
PFI1715w 
PF10_0232 
PF11_0504 
Erythrocyte binding antigen-181 
histone acetyltransferase GCN5, putative 
Plasmodium exported protein ,unknown function 
Chromodomain-helicase-DNA-binding protein 1 
homolog, putative 
Plasmodium exported protein (hyp11), unknown 
function 
Calcium 
Signaling 
 
PFF1185w--->  PF11_0142  ---> PF11_0239---
>MAL13P1.206 
0.037 PFF1185w  
PF11_0142 
PF11_0239 
MAL13P1.206 
Smarca -related protein 
ubiquitin domain containing protein 
calcium-dependent protein kinase, putative 
Na+ -dependent Pi transporter, sodium-dependent 
phosphate transporter 
 PFA0130c--->PFE1590w--->PFF1185w--->PF13_0036 0.036 PFA0130c 
PFE1590w 
PFF1185w 
PF13_0036 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Smarca -related protein 
DNAJ protein, putative 
 PFA0130c-->PFE1590w-->PFF1185w 0.007 PFA0130c 
PFE1590w 
PFF1185w 
Serine/Threonine protein kinase, FIKK family, putative 
early transcribed membrane protein 5, ETRAMP5 
Smarca -related protein 
Unknown PFA0125c-->PFE0570w-->PFE1590w--> PFF1185w--
>PF11_0277 
0.042 PFA0125c 
PFE0570w 
PFE1590w 
PFF1185w 
PF11_0277 
Erythrocyte binding antigen-181 
RNA pseudouridylate synthase, putative 
early transcribed membrane protein 5, ETRAMP5 
Smarca -related protein 
conserved Plasmodium protein, unknown function 
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reverse P. falciparum from resistant to chloroquine to sensitive 
phenotype. Another interesting drug-able signaling pathway is 
the last one in Table 1a with drug-able sites: PFE0570w and 
PF11_0277. It will be worthwhile validating the malaria 
chemotherapy basis of these two signaling pathways via the 
IC50 experiments as we did in Plaimas et al. [15].  
TABLE 1B.  DRUG-ABLE SITES ON THE PREDICTED SIGNALING 
PATHWAYS IN TABLES 2-8 OF Oyelade et al. [16]. 
 
Previous Gene 
IDs 
New Gene ID Human homologs E-value 
MAL4P1.18, 
PFD0090c 
MAL5P1.115, 
PFE0570w 
MAL5P1.150, 
PFE0750c 
MAL5P1.274, 
PFE1370w 
MAL6P1.304, 
PFF0590c 
MAL6P1.287, 
PFF0670w 
MAL6P1.264, 
PFF0785w 
MAL6P1.210, 
PFF1050w 
MAL6P1.176, 
PFF1220w 
PF10_0272 
PF11_0111 
PF11_0224 
PF11_0277, 
PF11_0278 
PF11_0506, 
PF11_0507 
MAL12P1.384, 
PFL1930w 
PF13_0197 
MAL13P1.202 
MAL13P1.206 
MAL13P1.256 
PF14_0257 
PF14_0463 
PF14_0632 
PF14_0678 
PF3D7_0402000 
PF3D7_0511500 
PF3D7_0515000 
PF3D7_0527500 
PF3D7_0612100 
PF3D7_0613800 
PF3D7_0616200 
PF3D7_0621800 
PF3D7_0625200 
PF3D7_1027800 
PF3D7_1110400 
PF3D7_1121600 
PF3D7_1126700 
PF3D7_1149000 
PF3D7_1239800 
PF3D7_1335100 
PF3D7_1339700 
PF3D7_1340900 
PF3D7_1351000 
PF3D7_1427900 
PF3D7_1448500 
PF3D7_1466300 
PF3D7_1471100 
XP_005
254442.
1 
AAS455
44.1 
XP_005
263522.
1 
AAA356
07.1 
BAG570
85.1 
XP_005
262249.
1 
AAI006
71.1 
AAC268
49.1 
CAA776
70.1 
BAC043
38.1 
NP_004
710.2 
XP_005
250006.
1 
XP_005
264475.
1 
AAN869
64.1 
XP_006
721356.
1 
AAC506
93.1 
AAT379
06.1 
EAW54
242.1 
BAB710
06.1 
NP_219
481.1 
NP_057
467.1 
EAW78
270.1 
BAB155
33.1 
1.2 
7.9 
0.45 
0.035 
0.016 
0.17 
0.15 
0.31 
0.067 
1.8 
0.041 
0.43 
0.13 
5.7 
4.8 
3.1 
0.37 
6.6 
0.021 
0.092 
0.031 
1.1 
0.52 
 
 
 
We next use Table 1b results to re-characterized our results in 
Tables 2-8 of Oyelade et al. This is presented in the supplementary 
material (SM). We listed for each protein in Table 1b, all signaling 
pathways (they participated in) of all groups of proteins as we have in 
Tables 2-8. This gave us 23 Tables: Table “PFD0090c”, etc. The 
green color in the 3rd column indicated that this pathways has been 
listed before for another protein(s). Doerig et al. [24] gave a brief on 
the biochemical characterization of P. falciparum cell cycle 
regulators. These included the Calmodulin-dependednt kinase (CDK) 
s, their likes and the cyclin-like proteins. On the 19th and 20th of 
November, 2014, doing a wild search with the words “Calmodulin” 
and “cyclin-like” on the PlasmoDB, we got respectively 115 and 8 
proteins. Looking for this in Table 1d above, we found only 3 
proteins (highlighted in red) from the “Calmodulin” group. We then 
searched for these 3 proteins from these 23 Tables. We highlighted 
them in red and we hypothesized them as important drug-able 
signaling pathways as these are needed for the control of the cell 
proliferation in P. falciparum. A very interesting one of the 23 Tables 
is Table “MAL13P1.202”. We re-produced this in Table 1e below: 
TABLE 1E.  
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Gene ID Name Minimum path p-value Details of genes 
 
Genes IDS 
 
Products 
MAL13P1.
202 
 
Cyclic 
Nucleotide 
PFB0190c---
>PFC0435w---
>PFE0660c ---> 
PF10_0254---
>MAL13P1.202 
0.033 PFB0190c  
PFC0435w 
 PFE0660c 
PF10_0254 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
conserved Plasmodium protein, unknown 
function 
conserved Plasmodium protein, unknown 
function 
PFC0435w---
>PFE0660c ---> 
PF08_0129---
>PF11_0111---
>MAL13P1.202 
0.028 PFC0435w 
PFE0660c 
PF08_0129 
PF11_0111 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
serine/threonine protein phosphatase, putative 
asparagine-rich antigen 
conserved Plasmodium protein, unknown 
function 
PFC0435w---> 
PFE0660c--->  
PFL2520w---
>MAL13P1.202 
 
 
 
0.016 PFC0435w 
PFE0660c 
PFL2520w 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
reticulocyte-binding protein 3 homologue 
conserved Plasmodium protein, unknown 
function 
PFC0435w---> 
PFE0660c---
>MAL13P1.202 
 
 
0.009 PFC0435w 
PFE0660c 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
conserved Plasmodium protein, unknown 
function 
PFB0190c--->  
PFC0435w---> 
PFE0660c---
>MAL13P1.202 
 
 
 PFB0190c 
PFC0435w 
PFE0660c 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
conserved Plasmodium protein, unknown 
function 
PFC0435w---> 
PFE0660c--->   
PF08_0129---
>MAL13P1.202 
 
 
 
0.016 PFC0435w 
PFE0660c 
PF08_0129 
MAL13P1.202 
conserved Plasmodium protein, unknown 
function 
purine nucleotide phosphorylase, putative 
serine/threonine protein phosphatase, putative 
conserved Plasmodium protein, unknown 
function 
FIKK PFA0130c---
>PFE1590w---
>PFL2520w---
>MAL13P1.202 
0.036 PFA0130c 
PFE1590w 
PFL2520w 
MAL13P1.202 
Serine/Threonine protein kinase, FIKK family, 
putative 
early transcribed membrane protein 5, 
ETRAMP5 
reticulocyte-binding protein 3 homologue 
conserved Plasmodium protein, unknown 
function 
PFA0130c---
>PFE1590w---
>MAL13P1.202 
0.007 PFA0130c 
PFE1590w 
MAL13P1.202 
Serine/Threonine protein kinase, FIKK family, 
putative 
early transcribed membrane protein 5, 
ETRAMP5 
conserved Plasmodium protein, unknown 
function 
PFA0130c---
>PFB0190c---
>PFE1590w---
>MAL13P1.202 
0.039 PFA0130c 
PFB0190c 
PFE1590w 
MAL13P1.202 
Serine/Threonine protein kinase, FIKK family, 
putative 
conserved Plasmodium protein, unknown 
function 
early transcribed membrane protein 5, 
ETRAMP5 
conserved Plasmodium protein, unknown 
function 
PFA0130c--
>PFE1590w-->  
PF08_0129--
>MAL13P1.202 
0.036 PFA0130c 
PFE1590w 
PF08_0129 
MAL13P1.202 
Serine/Threonine protein kinase, FIKK family, 
putative 
early transcribed membrane protein 5, 
ETRAMP5 
serine/threonine protein phosphatase, putative 
conserved Plasmodium protein, unknown 
function 
Unknown 
genes 
PFA0125c---
>PFE0570w--->  
PFE1590w--
>PF11_0277--
>MAL13P1.202 
0.036 PFA0125c 
PFE0570w 
PFE1590w 
PF11_0277 
MAL13P1.202 
erythrocyte binding antigen-181 
RNA pseudouridylate synthase, putative 
early transcribed membrane protein 5, 
ETRAMP5 
conserved Plasmodium protein, unknown 
function 
conserved Plasmodium protein, unknown 
function 
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And a very interesting signaling pathway of the ones listed 
in Table 1e above is the one highlighted in blue in the last two 
columns. This occurred in two other Tables of the 23 Tables. 
This pathway suggested another drug-able site: 
MAL13P1.202. The other two (sites) as indicted in this 
pathway have been found in two other pathways we have 
mentioned above.  
We took interest in the 4 enzymes in bold above and look 
up literature on them. We found the following: 
SN Protein Function  
1 MAL13P1.202 Conserved Plasmodium 
protein. 
Unknown function but 
expressed during blood 
stage of plasmodium 
 
2 PF11_0506 
antigen 332, 
DBL-like protein 
(Pf332) 
Immunological 
determinant 
Important for parasite 
invasion and survival in 
erythrocyte. Hence, good 
drug target. 
No literature on it has 
drug target 
 
No experimentally 
determined structure 
available in pdb. 
Most structurally 
similar proteins are 
1zro and 4qex with 
36.5 identity. 
 
 3 PFE0570w RNA pseudouridylate 
synthase, putative. 
Catalysis the single 
nucleotide modification 
in RNAs necessary for 
RNA folding and 
function especially in 
rRNA. 
It’s inhibition will alter 
protein sysnthesis. 
Hence, good drug 
target. 
No literature on it has 
drug target. 
No experimentally 
determined 
structure available 
in pdb. 
Most structurally 
similar protein 
2GML 31% 
identity. 
4 PF11_0277 Conserved Plasmodium 
protein. No known 
function. 
No literature on it has 
drug target 
 
No experimentally 
determined structure 
available in pdb. 
No experimental 
determined structure. 
Most structurally 
similar proteins are 
1f5n and 1dg3 with 
20.7 identity. 
 
 
From personal communication with Prof Dr Marcel 
Deponte, we arrived at starting further analysis on the RNA 
pseudouridylate synthase (putative). Since we found no PDB 
structure available for the protein, we build denovo structures 
for it as the following: We broke the protein sequence into 
domains using the EMBL INTERPRO protein sequence 
analysis and classification program. We arrived at 5 domains 
and then produced denovo structures for theses domains using 
the I-TASSER protein Structure and Function prediction 
(http://zhanglab.ccmb.med.umich.edu/I-TASSER/). For the 
first domain, we used the Molegro Virtual Docker to set up a 
virtual screening and the SDF file for the ligand was obtained 
from zinc.docking.org. The substrate is Uracil. We found that 
there are 7 analogues of Uracil that binds better to the 
predicted structure than Uracil itself. Interestingly, one of 
them has a reported antiplasmodial activity [25].This initial 
finding gave us hope in our on-going search for other 
inhibitors. Currently we are continuing this virtual screening 
to obtain other inhibitors. 
B.  RNA pseudouridylate synthase functional expression in 
E.coli and purification 
Optimization and Amplification of RNA Pseudouridylate 
Synthase Gene  
The Plasmodium falciparum 3D7 strain purified genomic 
DNA (gDNA) was collected from Prof. Dr. Michael Lanzer’s 
Laboratory, ImNeuenheimer Feld 324, University of 
Heidelberg, Heidelberg, Germany. After several attempts, the 
polymerase chain reaction (PCR) was carried out on the RNA 
pseudouridylate synthase gene (1:10 dilution) for 30cycles at 
95°Cfor 10mins, 95°C for 45secs, 53°C for 45secs, 68°C for 
2mins and 68°C for 10mins. The block temperature was 4°C. 
The forward and reverse primers with BamH1 and Not1 
restriction sites used (at 1µM) were 5´-
TTTTGGATCCATGTTTTTATTAACACATAACATAAA-
3´ and 5´-
TTTTGCGGCCGCTTAAAAAAAATATTCGTTGGGCATT
-3´, respectively. 
C.  Purification of Polymerase Chain Reaction (PCR) 
Product 
The PCR products were resolved on 1% agarose gel 
electrophoresis at 135V for 30mins (Fig. 3). The fragments 
were either purified from the gel using QIAquick gel 
extraction kit, Qiagen or from the whole PCR mix using 
QIAquickPCR purification kit, Qiagen, in accordance with 
manufacturer’s instructions. 
D. Cloning of RNA Pseudouridylate Synthase Gene 
The RNA pseudouridylate synthase gene was cloned into a 
pet28a vector using BamH1 and Not1 sites. The ligation was 
overnight at 16°C using 1:3 and 1:5 backbone: insert ratio. 
This was followed by transformation into Top10 competent 
cells and plating on kanamycin plates. The plates were later 
incubated overnight at 37°C (please see Fig. 4 for the 
overnight plates).  
E. Colony Polymerase Chain Reaction (PCR) 
The colonies were picked and subjected to PCR (30 cycles) 
using OneTaq quick load polymerase at 94°C for 5mins, 94°C 
for 30secs, 47°C for 1min, 68°C for 2mins and 68°C for 
5mins. The block temperature was 4°C. The forward and 
reverse primers used (at 1µM) were 5´-
TTTTGGATCCATGTTTTTATTAACACATAACATAAA-
3´ and 5´-GCTAGTTATTGCTCAGCGG    -3´, respectively. 
The PCR products were resolved on 1% agarose gel 
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electrophoresis at 135V for 30mins, and the potential right 
clones were identified (Fig. 5). 
F. Minipreps and Sequencing 
The LB media containing kanamycin (50µg/ml) was 
inoculated with the potential clones and allowed to grow 
overnight at 37°C. Thereafter, the plasmids were isolated and 
purified using QIAprep spin miniprep kit, Qiagen, in 
accordance with manufacturer’s instructions. Subsequently, 
the plasmids were sent for sequencing at GATC Biotech 
sequencing company, Heidelberg, Germany, using Sanger’s 
method (please see attachments for the results).  
G.  Expression and Purification  
Vector containing gene of interest was transformed into 
E.coli cells (Rosetta) and expressed for 12-16hrs at 37°C with 
vigorous shaking using ZYM-5052 autoinduction medium 
supplemented with kanamycin (50µg/ml). The cells were 
harvested at 4,000 rpm for 20mins at 4°C, quick frozen, and 
stored at -80°C. For purification of the protein (enzyme), the 
cell pellet was thawed and resuspended in lysis buffer 
containing 50mM KPi pH 8.0, 300mM NaCl, 10mM 
imidazole and protease inhibitor tablet (1:50ml of lysis 
buffer). This was followed by sonication (100% power, for 
6mins with 30secs waiting time in between. The membranes 
and cell debris were removed by centrifugation for 30mins at 
20, 000 rpm. All subsequent steps were performed at 4°C 
inside the cold room. Further steps were carried out using Bio-
scale mini profinity cartridge (Ni charged column), Bio-scale 
mini Bio-Gel p-6 desalting cartridge and Bio-Rad profinity 
Immobilized metal affinity chromatography (IMAC) machine 
in accordance with manufacturer’s instructions. The 
composition of buffers used include: wash buffer (50mM KPi 
pH 8.0, 300mM NaCl, 20mM imidazole and 10% glycerol) 
elution buffer (50mM KPi pH 7.5, 300mM NaCl, 500mM 
imidazole and 10% glycerol) and storage buffer (50mM 
Hepes-KOH pH 7.25, 150mM KCl, 10% glycerol and 0.1mM 
EDTA). The eluent was then subjected to size-exclusion 
chromatography by gel filtration using storage buffer and 
Superdex 200 101300 GL column as mobile and stationary 
phase, respectively. The filtration was done on AKTA start 
instrument according to manufacturer’s instructions (Fig. 6). 
The purity of the protein was further confirmed on 10% SDS-
PAGE which invariably revealed a single band with a size 
corresponding to that of RNA pseudouridylate synthase (Fig. 
7). The concentration of the protein was 0.67mg/ml, and 
stored at -800C. 
F.  Sequencing of Purified Protein by Mass Spectroscopy 
To identify the nature of the purified protein, a gel of the 
purified protein with a single band in colloidal coomassie 
staining was submitted for sequencing at 
ZentrumfürMolekulareBiologie der Universität Heidelberg, 
room 401, ImNeuenheimer Feld 282, Heidelberg, Germany. 
The results were retrieved and presented in Table 2 with some 
proteins that shared less significant percentage similarity with 
the sample of purified protein submitted. By implication, this 
might require further validation via testing the functionality of 
the protein. 
III.   RESULTS 
 
 
Fig. 3: Resolved PCR products on 1% agarose gel electrophoresis. M: marker, 
lane 1-3: RNA pseudouridylate synthase gene amplified fragment. 
 
Fig. 4: The 
overnight incubated plates at 370C. A: positive plate having both backbone 
(vector) and insert; B: negative plate having only backbone. 
 
A B 
1,695 bp 
158
3rd International Conference on African Development Issues (CU-ICADI 2016)
ISSN:2449-075X
Copyright © 2016 by Covenant University Press
 Fig. 5: Resolved colony PCR products on 1% agarose gel electrophoresis. 
1,695 bp M: marker, lane 4 (potential right clone containing RNA 
pseudouridylate synthase gene). 
 
 
Fig. 6: The elution profiles of the purified protein after size exclusion 
chromatography (gel filtration). 
 
 
Fig. 7: Purified RNA pseudouridylate synthase protein. M: marker, lane 1: 
Eluent A9, lane 2: Eluent A10, lane 3: Eluent A11, lane 4: Eluent A12 
corresponding to 68.45kD after gel filtration. 
 
TABLE II.    PROTEINS THAT WERE IDENTIFIED FROM MASS 
SPECTROSCOPY ANALYSIS WITH PERCENTAGE COVERAGE OF 
THE FRAGMENTS GENERATED FROM THE SAMPLE OF PURIFIED 
PROTEIN SUBMITTED 
S/N Proteins with similar fragments Percentage(%) 
coverage of 
fragments 
1 Bifunctionalpolymyxin resistance protein 
ArnA 
64 
2 Keratin, type I cytoskeletal 9  18 
3 Keratin, type II cytoskeletal 1  36 
4 Keratin, type I cytoskeletal 10  25 
5 Keratin, type II cytoskeletal 2 epidermal  25 
6 Trypsin  8 
7 Chaperone protein HtpG  30 
8 Chaperone protein DnaK  29 
9 30S ribosomal protein S1  21 
10 Threonine--tRNA ligase  8 
11 Keratin, type II cytoskeletal 5  10 
12 Keratin, type I cytoskeletal 14  9 
 
IV.   DISCUSSION AND CONCLUSION 
The increasing failure of the present antimalarial drugs is 
an alarming signal necessitating the development of novel 
drugs and identify novel drug targets in Pf. We have identified 
RNA Pseudouridylate Synthasein Pf and successfully carried 
out a functional cloning of its open reading frame in E. coli. 
The molecular weight of the protein expressed by E. coli is 
similar to that of plasmodium RNA Pseudouridylate Synthase. 
Our finding is consistent with that of Njuguna et al [26]. The 
biochemical impairment in ribosomal activity via inhibition of 
this enzyme is expected to manifest as decreased translational 
fidelity in Pf. [27]. Ribosomes play a critical role in protein 
synthesis, hence, in fast growing organisms like blood stage 
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Pf, characterizing and inhibiting enzymes associated with 
ribosomes is highly promising as drug targets. It is important 
to note that RNA Pseudouridylate Synthaseis for the first time 
completely expressed in E. coli and purified. This is an 
important step to be able to establish its 3D structure via X-ray 
crystallography or NMR and the assessment of this protein as 
a novel drug target. For the establishment of its 3D structure, 
we are working on two proteins in this direction, that included 
the one studied in this paper, via a PhD research work in 
collaboration with the Institute of Pharmacy and Molecular 
Biotechnology (IPMB), Heidelberg University, Faculty of 
Biochemistry, Tuebingen, University and the department of 
Biochemistry at the Cambridge University. 
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